홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

피페리딘,1-[3-[3-(4-클로로페닐)프로폭시]프로필]-

Pitolisant

HCID 9948102
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
362665-56-3
표준 SMILES
Clc1ccc(CCCOCCCN2CCCCC2)cc1
InChIKey
NNACHAUCXXVJSP-UHFFFAOYSA-N
분자식
C17H26ClNO
평균 분자량
295.8 g/mol
단동위원소 질량
295.1702921

개요

Pitolisant is an organochlorine compound.

이름 및 식별자

우선 이름
Pitolisant
IUPAC
1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
현지명
피페리딘,1-[3-[3-(4-클로로페닐)프로폭시]프로필]-
영어명
Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-
분자식
C17H26ClNO
분자량
295.85

이름 및 동의어

Pitolisant362665-56-31-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidineTIPROLISANT1-(3-(3-(4-Chlorophenyl)propoxy)propyl)piperidineBF2.649HBS-1011-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine4BC83L4PIYBF-2649BF-2.649DTXSID30957654
이름 더 보기
피페리딘,1-[3-[3-(4-클로로페닐)프로폭시]프로필]-TirolisantTilolisonPitolisomtTiprolisant PitolisantBF 2.649Chlorophenyl)propoxy)propyl)piperidine
N07XX11pitolisantumWakix, europeRefChem:57771DTXCID60207876Pitolisant (BF2.649)wakixMFCD18782650

데이터베이스 식별자

CAS
362665-56-3
PubChem CID
9948102
DTXSID
DTXSID30957654
ChEMBL
CHEMBL462605
ChEBI
CHEBI:134709
UNII
4BC83L4PIY
EC Number
111-217-6

물성

구조 계산 물성

XLogP
4.3
극성 표면적
12.5 Ų
수소 결합 공여자 수
0
수소 결합 수용자 수
2
회전 가능 결합 수
8
무거운 원자 수
20
형식 전하
0
복잡도
235

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 4건

Breast Feeding; Lactation; Milk, Human; Histamine H3 Antagonists; Wakefulness-Promoting Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine (Orphan designations)

EMA approved medicines: Human medicine

물리화학적 성질

끓는 점
398.7 · 398.7±32.0 °C(Predicted)
밀도
1.056 · 1.056
저장 조건
-20 °C · Sealed in dry,Store in freezer, under -20°C
용해도
에 용해됨DMSO
물리적 상태
가루
산도 계수 (pKa)
9.41 · 9.41±0.10(Predicted)
색상
Colorless to light yellow

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H361fd (100%): Suspected of damaging fertility; Suspected of damaging the unborn child [Warning Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

유해성 정보

Hazard Classes and CategoriesRepr. 2 (100%)

독성 정보

Hepatotoxicity · 1건

In placebo-controlled trials of pitolisant in patients with narcolepsy, minor serum aminotransferase elevations occurred in a small proportion of patients during therapy, but rates of enzyme elevations were similar to those in placebo recipients. In preregistration trials, there were no instances of clinically apparent liver injury or serum aminotransferase elevations with jaundice attributable to pitolisant. Since its approval in Europe in 2017 and the United States in 2020, there have been no publications describing clinically apparent liver injury due to pitolisant.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

신호 어
Warning
유해·위험 문구
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H315

화학 및 산업

약리 정보

ATC Code · 2건

N - Nervous system

QN - Nervous system

Protein BindingThe serum protein binding of pitolisant is approximately 91% to 96%. Pitolisant is mainly bound to serum albumin and alpha-1 glycoprotein.
Pharmacodynamics · 1건

Pitolisant promotes wakefulness in narcolepsy by enhancing histaminergic signalling in the central nervous system. It does not significantly bind to H1, H2, or H4 receptors. In patients with narcolepsy in presence or absence of cataplexy, treatment of pitolisant was associated with an improvement in the level and duration of wakefulness and daytime alertness assessed by objective measures of ability to sustain wakefulness (e.g. Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) Scores) and attention (e.g. Sustained Attention to Response Task (SART)). Pitolisant also improved the frequency and severity of narcolepsy-associated cataplexy. Pitolisant acts as a blocker at hERG channels. In two QT studies, supra-therapeutic doses of pitolisant (3-6-times the therapeutic dose, that is 108 mg to 216 mg) produced mild to moderate prolongation of QTc interval (10-13 ms).

Mechanism of Action · 1건

Signalling of histaminergic neurons plays a key role in activating the arousal system with widespread projections to the whole brain via activating orexin receptors. Narcolepsy is characterized by insufficient neurotransmission by orexins, or hypocretins, which are excitatory peptides released by neurons located from the lateral hypothalamus. These neurons project to aminergic neurons, such as histaminergic or noradrenergic neurons, that are responsible for the effects of orexin and control of wakefulness. Histamine H3 receptors are presynaptic inhibitory autoreceptors that are located in the cerebral cortex, hypothalamus, hippocampus, and basal ganglia. H3 receptors promote the re-uptake of histamine at synaptic terminals and attenuate further histamine release into the synapse. By blocking H3 autoreceptors and increasing the levels of histamine transmitters at the synapse, pitolisant enhances the activity of histaminergic neurons and promotes wakefulness. Inverse agonism of pitolisant at H3 receptors also leads to enhanced synthesis and release of endogenous histamine over the basal level. Pitolisant acts as a high-affinity competitive antagonist (Ki 0.16 nM) and as an inverse agonist (EC50 1.5 nM) at the human H3 receptor and mediates its pharmacological action at the presynaptic level. It is thought to bind to the antagonist binding site of the H3 receptor, which is located within the transmembrane core just below the extracellular loops. Piperidines form a salt bridge with Glu206 in the membrane-spanning segment, and the hydroxyl of Tyr374 is H-bonded with the central oxygen of piperidine. Pitolisant displays high selectivity for H3 receptors compared to other histamine receptor subtypes. Pitolisant also modulates acetylcholine, noradrenaline and dopamine release in the brain by increasing the levels of neurotransmitters but does not increase dopamine release in the stratal complex, including the nucleus accumbens. At lower nanomolar concentrations, pitolisant acts as an inverse agonist at H3 receptors and enhances the release of endogenous histamine over the basal level.

관련 반응

6건
반응 기록 만들기
HRID 121161 반응식
HRID 121161생성물로
HRID 222215 반응식
HRID 222215생성물로
HRID 604383 반응식
HRID 604383생성물로
HRID 1376166 반응식
HRID 1376166생성물로
HRID 1804758 반응식
HRID 1804758생성물로
HRID 2329564 반응식
HRID 2329564생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
Nikkaji
J1.574.747A
Biological Half-LifePitolisant has a plasma half-life of 10-12 hours. After administration of a single dose of 35.6 mg, the median half-life of pitolisant was approximately 20 hours.
Metabolism/Metabolites · 1건

Pitolisant is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4 in the liver. The major non-conjugated metabolites are BP2.941 (piperidine N-oxide) and BP2.951 (5-aminovaleric acid). Metabolites can further undergo conjugation with glycine or glucuronic acid, and oxidation to a minimal extent. Most metabolites of pitolisant do not retain considerable pharmacological activities. Several conjugated metabolites were also identified; the major conjugated inactive metabolite was a glycine conjugate of the acid metabolite of O-dealkylated desaturated pitolisant and a glucuronide of a ketone metabolite of monohydroxy desaturated pitolisant. Due to its extensive metabolism in the liver, the systemic exposure of pitolisant thus adverse events of the drug may be elevated in case of compromised liver function. The dosage adjustments for pitolisant is advised in patients with moderate hepatic impairment.

FDA Pharmacological Classification · 6건

4BC83L4PIY

PITOLISANT

Established Pharmacologic Class [EPC] - Histamine-3 Receptor Antagonist/Inverse Agonist

Mechanisms of Action [MoA] - Histamine H3 Receptor Inverse Agonists

Mechanisms of Action [MoA] - Histamine H3 Receptor Antagonists

Mechanisms of Action [MoA] - Cytochrome P450 3A4 Inducers

Absorption, Distribution and Excretion · 4건

Pitolisant is rapidly and well absorbed following oral administration, resulting in the drug being 90% absorbed. In healthy individuals receiving an oral dose of 20 mg, the Cmax was approximately 30 ng/mL. Following oral administration of pitolisant 35.6 mg once daily, the mean steady state Cmax and AUC were 73 ng/mL and 812 ngxhr/mL, respectively. The Tmax was typically reached approximately 3 hours following administration. Following repeated dosing, the steady-state plasma concentration is achieved after 5-6 days of administration but the inter-individual variability in the time to reach steady-state is reported to be high. The absolute bioavailability of pitolisant has not been determined.

Following hepatic metabolism, about 63% of total elimination occurs via renal excretion into the urine as an inactive non-conjugated metabolite BP2.951 and a glycine conjugated metabolite. About 25% of the total dose administered is excreted through expired air as metabolites, and a small fraction (<3%) of drug can be recovered in faeces.

Following single and multiple oral dosing of pitolisant to healthy male adults at doses between 1 and 240 mg, the apparent volume of distribution (V/F) ranges from 1100 to 2825 L. Pitolisant is thought to be equally distributed between red blood cells and plasma. Following intravenous administration of pitolisant in rats and monkeys, the apparent Vd at steady-state was approximately 10-fold greater than total body water. Pitolisant crosses the blood-brain barrier and placenta, and was found in milk in rats.

The apparent oral clearance (CL/F) of pitolisant was 43.9 L/hr following a single dose of 35.6 mg. The clearance rate is expected to be lower with increasing age.

응용 분야 · 1건

용도Pitolisant is a potent and selective nonimidazole inverse agonist at the recombinant human histamine H3 receptor. Pitolisant is also used in the treatment of patients with narcolepsy, excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep, hypnagogic hallucinations and sleep paralysis